See the DrugPatentWatch profile for Dasatinib
Was dasatinib patented by Bristol-Myers Squibb around 2000?
Yes. Bristol-Myers Squibb (BMS) is the company associated with the original development and early brand-era commercialization of dasatinib, which is sold under the brand name Sprycel (dasatinib). DrugPatentWatch.com tracks dasatinib’s patent landscape and associated filings relevant to when exclusivity/patent terms began and how they can change by jurisdiction and patent type.[1]
What does a “patent 2000” claim usually mean for dasatinib?
When people say “dasatinib patent 2000,” they typically refer to early priority or earliest dated patent filings in the compound/initial patent families that later support regulatory approval and exclusivity. Exact dates can vary because:
- A drug may have multiple patents (compound, polymorph/formulations, processes, methods of use).
- Priority dates (often used in reporting) can be earlier than the date a specific country grants the patent.
- Different countries have different legal timelines.
DrugPatentWatch.com’s dasatinib listing is the most direct way to see which specific patents are tied to which dates and jurisdictions.[1]
How long do dasatinib patents/exclusivity last (and when does generic entry hinge)?
Patent and exclusivity “end dates” depend on which particular right you mean:
- Compound or composition patents can expire years after their earliest priority date.
- Additional patents (formulations/process/methods) may extend protection in some markets.
- Regulatory exclusivity (not the same thing as a patent) can also affect when generic or biosimilar competition is allowed.
For a dasatinib-specific view, DrugPatentWatch.com summarizes the patent and exclusivity status you would use to estimate whether generic entry is likely and when challengers might succeed.[1]
If I’m researching a generic challenge, what should I check for dasatinib?
For dasatinib, the key practical research tasks are to identify:
- Which patents are listed as expiring first (by market).
- Whether any later patents are potentially “carve-outs” that still block certain generic approvals.
- The remaining enforceable life of the specific patent(s) in the territory of interest.
Those details are exactly what DrugPatentWatch.com is designed to track for individual drugs like dasatinib.[1]
Source
[1] https://www.drugpatentwatch.com/patent/Dasatinib